Related Experiment Video
Updated: Aug 9, 2025

04:46
Author Spotlight: Innovative Techniques and Future Directions in Stroke Research
Published on: May 5, 2023
4.3K
Advances in Neurological Diseases and Stroke
Narayanaswamy Venketasubramanian1
1Raffles Neuroscience Centre, Raffles Hospital, Singapore 188770, Singapore.
Journal of Cardiovascular Development and Disease
|February 24, 2023
Abstract:
Neurological diseases are a major cause of death and disability worldwide [...].
Related Concept Videos
Parkinson's Disease: Overview
639
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
639
Alzheimer's Disease: Overview
591
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
591
Alzheimer's Disease: Treatment
235
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
235

